Clinical Trials

Inclusion Criteria: 

• Subject must be ≥ 18 years of age at signing of informed consent. 
• Subject must be diagnosed with relapsed or refractory DLBCL (including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) and scheduled to receive treatment with Yescarta. 
• Female subjects of childbearing potential who are sexually active and male subjects who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 30 days after the last dose of defibrotide. 
• Subject must be able to understand and sign written informed consent.

Exclusion Criteria:

• Subject is currently receiving dialysis or expected to receive dialysis. 
• Subject has used any investigational anticancer agent within 3 weeks prior to the first dose of defibrotide, or is using or plans to use any investigational agent during the study. 
• Subject has previously been treated with CAR-T therapy. 
• Hemodynamic instability requiring vasopressors or uncontrolled hypertension with persistent systolic blood pressure > 180. 
• Subject has clinically significant active bleeding, history of intracranial bleeding, or is at risk for intracranial bleeding as determined by the Investigator. 
• Subject plans to use any medication that increases the risk of bleeding. 
• Subject is pregnant or lactating and does not agree to stop breastfeeding. 
• Subject has a known history of hypersensitivity to defibrotide or any of the excipients. 
• Subject has primary CNS lymphoma.